Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fratricide-Resistant Autologous Chimeric Antigen Receptor T Cells Targeting CCR9 for the Treatment of T Cell Acute Lymphoblastic Leukaemia/ Lymphoma

NCT07300683 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT07300683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07300683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fratricide-Resistant Autologous Chimeric Antigen Receptor T Cells Targeting CCR9 for the Treatment of T Cell Acute Lymphoblastic Leukaemia/ Lymphoma
Lead sponsor
University College, London
Phase
Phase 1
Overall status
Recruiting
Start date
November 11, 2025
Completion date
December 31, 2042
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t cell acute lymphoblastic leukemia, t cell lymphoblastic lymphoma